Skip to main content

Table 1 Patient characteristics

From: Ophthalmic manifestations are associated with reduced tear lymphotoxin-α levels in chronic ocular graft-versus-host disease

Characteristics oGVHD (n=22) Control (n=17) P value
Age, years1 31.52 ± 9.63 26.86 ± 9.86 0.173
Gender2    0.092
 Male, n (%) 11 (50.0%) 13 (76.47%)  
 Female, n (%) 11 (50.0%) 4 (23.53%)  
Hematologic diagnosis, n (%)   0.711
 AML (acute myelogenous leukemia) 15 (68.2%) 10 (58.8%)  
 ALL (acute lymphoblastic leukemia) 4 (18.2%) 5 (29.4%)  
 MDS (myelodysplastic syndromes) 3 (13.6%) 2 (11.8%)  
HLA matching    0.291
 Haploidentical 18 (81.8%) 15 (88.2%)  
 Non-identical 0 1 (5.9%)  
 Identical 4 (18.2%) 1 (5.9%)  
Other current organ involvement in cGVHD    0.073
 Gastrointestinal tract 2 (9.1%) 2 (11.8%)  
 Lung 4 (18.2%) 1 (6.2%)  
 Liver 9 (40.9%) 0  
 Oral cavity 19 (86.4%) 1 (6.2%)  
 Skin 20 (90.9%) 7 (41.2%)  
Current systemic immunosuppressive treatment    0.827
 None 6 (27.3%) 5 (29.4%)  
 Calcineurin inhibitor 4 (18.2%) 3 (17.6%)  
 Steroid 5 (22.7%) 2 (11.8%)  
 Calcineurin inhibitor + steroid 7 (31.8%) 7 (41.2%)  
Period after HSCT, months 19 ± 19 15 ± 11 0.084
  1. Mean values ± SD, median ± IQR, or percentages were shown as above. There were no significant differences in age1 (P = 0.173) or gender2 (P = 0.092) between oGVHD patients (n=22) and controls (n=17)